Company intelligence / Profile preview
Lamassu Bio
Durham, North Carolina, United Stateslamassupharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 1
01
Overview
The company has a pancreatic cancer therapeutic (RABI-767) that has progressed to trials in under 1.5 years. They also have SA53, a new therapeutic for p53 wild-type sarcomas that has shown significant potency, efficacy, and safety in preclinical models.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small moleculesBiologics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Mayo ClinicArrivo BioVenturesCleveland Clinic Taussig Cancer CenterCleveland Clinic Children's Pediatric Hematology and Oncology Department
Beyond the preview
Go deeper on Lamassu Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lamassu Bio.